Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Therapeutics Inks SNP Collaboration with Oxagen

Premium

HAYWARD, Calif.--Lynx Therapeutics announced that it will collaborate with Oxagen of Oxford, UK, to discover and validate disease-associated single-nucleotide polymorphisms (SNPs). The program will initially focus on inflammatory bowel disease, but may be extended to other common disorders. No financial terms were disclosed.

Lynx will apply its proprietary SNP-extracting and genotyping technologies to identify disease-associated SNPs from large, well characterized patient populations available to Oxagen through its clinical collaborators. Oxagen will map and further refine the regions of association defined by these SNPs to locate disease genes and identify functional polymorphisms within them.

Filed under

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.